A good deal rests on the race to develop a weight-loss pill that will widen the market beyond today's injectable "fat jabs".

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

The US Food and Drug Administration (FDA) granted approval for a second treatment for metabolic dysfunction-associated ...

Here are some of the stories Wall Street is watching on Friday, Aug. 22. Stocks and cryptocurrencies surged after Fed Chair ...

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 ...

Drugmaker Novo Nordisk (NVO) will offer a reduced 2025 yearly bonus to its employees in Denmark due to the company’s lowered ...

Novo Nordisk (NVO) stock in focus as company decides to cut 2025 bonuses for employees in Denmark amid cost-cutting measures ...

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

In July, Trump had threatened to lift pharmaecutical tariffs to 200%, but speaking on CNBC on 5 August, Trump said they could eventually go as high as 250%. "We want pharmaceuticals made in our ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...